Current
T-Therapeutics
Life Sciences
•
East of England
•
Early Stage
•
2025
T-Therapeutics is a next-generation T-cell receptor (TCR) company, spun-out from the University of Cambridge, to create safe and effective treatments for cancer and autoimmune disease. It's developing a pipeline of first-in-class drugs, reshaping the clinical landscape for patients.
Looking for funding?
We’ve already helped hundreds of ambitious businesses in the UK and Ireland to accelerate their growth. If you’re looking for a minority investment partner that can provide long-term, flexible funding and support, please get in touch with our team today.
